Healthcare policy issues as they relate to the pharmaceutical industry including drug pricing and biosimilars
2025 · 3rd Quarter (July 1 - Sep 30)
AMGEN, INC.
Filed by MILLER STRATEGIES, LLC.
Open official filingSource-reported fields
Filing overview
- Type
- 3rd Quarter - Report
- Posted
- Oct 20, 2025
- Income
- $60,000.00
- Expenses
- Not reported
- Registrant
- MILLER STRATEGIES, LLC
- Client
- AMGEN, INC.
- Filing UUID
- 93bacb67-f0fc-476f-bf00-ead448762181
- Termination date
- Not reported
Literal source text
Lobbying issues and bill citations
Issues related to drug pricing, biosimilars, Medicare Part D and Medicare Part B; H.R. 3517 - Increasing Access to Osteoporosis Testing for Medicare Beneficiaries Act of 2021
Literal federal measure citations: H.R. 3517
Issues related to visas
Relationship and amount limits
Bill links use only the filing year’s mathematically derived Congress plus the literal measure type and number in the issue description. Unmatched citations remain plain text. Politically.com does not join on names, infer advocacy positions, combine amendments, or calculate totals across filings.